Two Phase 3 Trials of CF Triple Combo Therapy to Open in 2020, Proteostasis Says
Proteostasis met with UK regulators before announcing plans to soon open two pivotal studies, CHOICES and MORE, into its triple combination CFTR modulators. Read more about it here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.